Patents by Inventor Matthias Urmann

Matthias Urmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8946212
    Abstract: Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals The invention relates to annelated N-heterocyclic sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: February 3, 2015
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Matthias Urmann, Maike Glien, Hans Matter, Eugen Falk, Ulrike Wendler
  • Patent number: 8748483
    Abstract: The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: June 10, 2014
    Assignee: SANOFI
    Inventors: Harm Brummerhop, Siegfried Stengelin, Hubert Heuer, Susanne Kilp, Andreas Herling, Thomas Klabunde, Dieter Kadereit, Matthias Urmann
  • Patent number: 8735586
    Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula I, wherein R0; R1; R2; R3; R4; R5; A1; A2; A3; A4, Q and J have the meanings indicated in the claims. The present invention provides a direct copper catalyzed regioselective process to a wide variety of unsymmetrical, multifunctional N-substituted benzimidazoles or azabenzimidazoles of formula I starting from 2-halo-nitroarenes and N-substituted amides.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: May 27, 2014
    Assignee: Sanofi
    Inventors: Jorge Alonso, Andreas Lindenschmidt, Marc Nazaré, Matthias Urmann, Nis Halland, Omar Rkyek
  • Patent number: 8716317
    Abstract: The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 6, 2014
    Assignee: Sanofi
    Inventors: Stefanie Keil, Matthias Urmann, Maike Glien, Hans Matter, Harry Randall Munson, Jr., Ulrike Wendler
  • Patent number: 8487109
    Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), wherein R1; R2; R3; R4; R5; J and W have the meanings indicated in the claims. The present invention provides an efficient and general palladium-catalyzed coupling process for aryl tosylates with terminal alkynes to a wide variety of substituted, multifunctional aryl-1-alkynes of the formula I.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: July 16, 2013
    Assignee: Sanofi
    Inventors: Omar Rkyek, Marc Nazare, Andreas Lindenschmidt, Matthias Urmann, Nis Halland, Jorge Alonso
  • Patent number: 8420812
    Abstract: A process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), wherein D, J and W have the meanings indicated in the claims. The present invention provides an efficient and general palladium-catalyzed coupling process of heteroaryl tosylates with terminal alkynes to a wide variety of substituted, multifunctional heteroaryl-1-alkynes of the formula I.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: April 16, 2013
    Assignee: Sanofi
    Inventors: Omar Rkyek, Marc Nazare, Andreas Lindenschmidt, Jorge Alonso, Matthias Urmann, Nis Halland
  • Patent number: 8344004
    Abstract: The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 1, 2013
    Assignee: Sanofi
    Inventors: Karl Schoenafinger, Stefanie Keil, Matthias Urmann, Hans Matter, Maike Glien, Wolfgang Wendler, Ulrike Wendler, legal representative
  • Patent number: 8329725
    Abstract: The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: December 11, 2012
    Assignee: Sanofi
    Inventors: Stefanie Keil, Matthias Urmann, Wolfgang Wendler, Ulrike Wendler, Maike Glien, Hans Matter, Eugen Falk
  • Patent number: 8283476
    Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula I, wherein R0; R1; R2; R3; R4; R5; A1; A2; A3; A4, Q and J have the meanings indicated in the claims. The present invention provides a direct transition metal catalyzed process to a wide variety of multifunctional 2H-indazoles or 2H-azaindazoles of the formula (I) from 2-halo-phenylacetylenes or (2-sulfonato)phenylacetylenes and monosubstituted hydrazines.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: October 9, 2012
    Assignee: Sanofi
    Inventors: Nis Halland, Marc Nazare, Andreas Lindenschmidt, Jorge Alonso, Omar Rkyek, Matthias Urmann
  • Publication number: 20120172400
    Abstract: The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 5, 2012
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Matthias Urmann, Wolfgang Wendler, Ulrike Wendler, Maike Glien, Hans Matter, Harry Randall Munson, JR.
  • Patent number: 8188282
    Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula I, wherein R0; R1; R2; R3; R4; R5; A1; A2; A3; A4, Q and J have the meanings indicated in the claims. The present invention provides a direct palladium catalyzed, regioselective process to a wide variety of unsymmetrical, multifunctional N-substituted benzimidazoles or azabenzimidazoles of formula I starting from 2-halo-nitroarenes and N-substituted amides useful for the production of pharmaceuticals, diagnostic agents, liquid crystals, polymers, herbicides, fungicidals, nematicidals, parasiticides, insecticides, acaricides and arthropodicides.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: May 29, 2012
    Assignee: Sanofi-Aventis
    Inventors: Jorge Alonso, Andreas Lindenschmidt, Marc Nazare, Nis Halland, Omar Rkyek, Matthias Urmann
  • Publication number: 20120122853
    Abstract: Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals The invention relates to annelated N-heterocyclic sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: May 22, 2009
    Publication date: May 17, 2012
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Matthias Urmann, Wolfgang Wendler, Maike Glien, Hans Matter, Eugen Falk, Ulrike Wendler
  • Patent number: 8173674
    Abstract: The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: May 8, 2012
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Matthias Urmann, Karl Schoenafinger, Wolfgang Wendler, Maike Glien, Hans-Ludwig Schaefer, Eugen Falk
  • Patent number: 8088925
    Abstract: The present invention relates to compounds of the formula I, which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: January 3, 2012
    Assignee: Sanofi-Aventis
    Inventors: Michael Wagner, Matthias Urmann, Volkmar Wehner, Martin Lorenz, Armin Bauer, Marc Nazare, Hans Matter
  • Patent number: 8026375
    Abstract: The present invention relates to a process for the regioselective synthesis of compounds of the formula I, wherein R0; R1; R2; R3; R4; R5; R6; A1; A2; A3; A4, Q, T and J have the meanings indicated in the claims. The present invention provides a direct transition metal catalyzed process to a wide variety of multifunctional N-aminoindole or N-amino-azaindoles of the formula I from 2-halo-phenylacetylenes or (2-sulfonato)phenyl-acetylenes and N,N-disubstituted hydrazines, useful for the production of pharmaceuticals, diagnostic agents, liquid crystals, polymers, herbicides, fungicidals, nematicidals, parasiticides, insecticides, acaricides and arthropodicides.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: September 27, 2011
    Assignee: Sanofi-Aventis
    Inventors: Nis Halland, Marc Nazare, Andreas Lindenschmidt, Omar Rkyek, Matthias Urmann, Jorge Alonso
  • Publication number: 20110224263
    Abstract: The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: June 9, 2010
    Publication date: September 15, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Karl SCHOENAFINGER, Stefanie KEIL, Matthias URMANN, Hans MATTER, Maike GLIEN, Wolfgang WENDLER, Ulrike Wendler
  • Publication number: 20110207738
    Abstract: The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: May 22, 2009
    Publication date: August 25, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Matthias Urmann, Wolfgang Wendler, Maike Glien, Hans Matter, Eugen Falk
  • Patent number: 7910612
    Abstract: The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, wherein the various unnamed substituents are defined herein. The compounds are suitable for the treatment of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: March 22, 2011
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Karl Schoenafinger, Hans Matter, Matthias Urmann, Maike Glien, Wolfgang Wendler, Hans-Ludwig Schaefer, Eugen Falk
  • Patent number: 7858647
    Abstract: The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 28, 2010
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Hans Matter, Karl Schoenafinger, Matthias Urmann, Maike Glien, Wolfgang Wendler, Hans-Ludwig Schaefer, Eugen Falk
  • Patent number: 7851493
    Abstract: The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: December 14, 2010
    Assignee: Sanofi-Aventis
    Inventors: Patrick Bernardelli, Stefanie Keil, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee, Corinne Terrier, Herve Minoux